News

« Back

A researcher from the Neurobiology of Hearing group participates in a clinical trial of a new treatment for hereditary angioedema

Dr. Maria Luisa Baeza from the Neurobiology of Hearing group has participated in a Phase III clinical study ((EudraCT 2013-000916-10, ClinicalTrials.gov NCT01912456) to evaluate the efficacy and safety of the C-1 inhibitor CSL830 in the treatment of hereditary angioedema The results of this trial indicate that the subcutaneous administration of CSL830 decreases the number of attacks of hereditary angioedema per month, with the majority of patients presenting a low profile of side effects. This work has been published in the prestigious New England Journal of Medicine

Longhurst et al. Prevention of Hereditary Angioedema Attacks with Subcutaneous C1-Inhibitor. NEJM 2017 Mar 23;376(12):1131-1140

 

Average (0 Votes)
The average rating is 0.0 stars out of 5.


No comments yet. Be the first.